291 related articles for article (PubMed ID: 29163783)
1. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
Marcq E; Waele J; Audenaerde JV; Lion E; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits ELJ
Oncotarget; 2017 Oct; 8(52):89722-89735. PubMed ID: 29163783
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
Marcq E; Siozopoulou V; De Waele J; van Audenaerde J; Zwaenepoel K; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits EL
Oncoimmunology; 2017; 6(1):e1261241. PubMed ID: 28197385
[TBL] [Abstract][Full Text] [Related]
3. Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
Marcq E; Audenaerde JRV; Waele J; Jacobs J; Loenhout JV; Cavents G; Pauwels P; Meerbeeck JPV; Smits EL
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31455014
[TBL] [Abstract][Full Text] [Related]
4. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
Salaroglio IC; Kopecka J; Napoli F; Pradotto M; Maletta F; Costardi L; Gagliasso M; Milosevic V; Ananthanarayanan P; Bironzo P; Tabbò F; Cartia CF; Passone E; Comunanza V; Ardissone F; Ruffini E; Bussolino F; Righi L; Novello S; Di Maio M; Papotti M; Scagliotti GV; Riganti C
J Thorac Oncol; 2019 Aug; 14(8):1458-1471. PubMed ID: 31078776
[TBL] [Abstract][Full Text] [Related]
5. The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.
Marcq E; Van Audenaerde JRM; De Waele J; Merlin C; Pauwels P; van Meerbeeck JP; Fisher SA; Smits ELJ
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466653
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
Awad MM; Jones RE; Liu H; Lizotte PH; Ivanova EV; Kulkarni M; Herter-Sprie GS; Liao X; Santos AA; Bittinger MA; Keogh L; Koyama S; Almonte C; English JM; Barlow J; Richards WG; Barbie DA; Bass AJ; Rodig SJ; Hodi FS; Wucherpfennig KW; Jänne PA; Sholl LM; Hammerman PS; Wong KK; Bueno R
Cancer Immunol Res; 2016 Dec; 4(12):1038-1048. PubMed ID: 27856426
[TBL] [Abstract][Full Text] [Related]
7. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
[TBL] [Abstract][Full Text] [Related]
8. P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.
Pezzuto F; Lunardi F; Vedovelli L; Fortarezza F; Urso L; Grosso F; Ceresoli GL; Kern I; Vlacic G; Faccioli E; Schiavon M; Gregori D; Rea F; Pasello G; Calabrese F
Front Oncol; 2021; 11():653497. PubMed ID: 33828993
[TBL] [Abstract][Full Text] [Related]
9. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
Watanabe T; Okuda K; Murase T; Moriyama S; Haneda H; Kawano O; Yokota K; Sakane T; Oda R; Inagaki H; Nakanishi R
Oncotarget; 2018 Apr; 9(29):20769-20780. PubMed ID: 29755688
[TBL] [Abstract][Full Text] [Related]
10. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy.
Harber J; Kamata T; Pritchard C; Fennell D
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518291
[TBL] [Abstract][Full Text] [Related]
11. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.
Imai Y; Hasegawa K; Matsushita H; Fujieda N; Sato S; Miyagi E; Kakimi K; Fujiwara K
Oncol Lett; 2018 May; 15(5):6457-6468. PubMed ID: 29616115
[TBL] [Abstract][Full Text] [Related]
12. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
[TBL] [Abstract][Full Text] [Related]
13. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
Jing W; Gershan JA; Weber J; Tlomak D; McOlash L; Sabatos-Peyton C; Johnson BD
J Immunother Cancer; 2015; 3(1):2. PubMed ID: 25614821
[TBL] [Abstract][Full Text] [Related]
14. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Hsu PC; Yang CT; Jablons DM; You L
Biomedicines; 2018 Dec; 6(4):. PubMed ID: 30544524
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion.
Bruss C; Kellner K; Albert V; Hutchinson JA; Seitz S; Ortmann O; Brockhoff G; Wege AK
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174080
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
Riganti C; Lingua MF; Salaroglio IC; Falcomatà C; Righi L; Morena D; Picca F; Oddo D; Kopecka J; Pradotto M; Libener R; Orecchia S; Bironzo P; Comunanza V; Bussolino F; Novello S; Scagliotti GV; Di Nicolantonio F; Taulli R
Oncoimmunology; 2018; 7(3):e1398874. PubMed ID: 29399399
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Valmary-Degano S; Colpart P; Villeneuve L; Monnien F; M'Hamdi L; Lang Averous G; Capovilla M; Bibeau F; Laverriere MH; Verriele-Beurrier V; Ben Rejeb H; Dartigues P; Hommell-Fontaine J; Gilly FN; Isaac S; Mery E;
Eur J Surg Oncol; 2017 Oct; 43(10):1915-1923. PubMed ID: 28619621
[TBL] [Abstract][Full Text] [Related]
18. The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.
Kozłowski M; Borzyszkowska D; Cymbaluk-Płoska A
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359346
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.
Rovers S; Janssens A; Raskin J; Pauwels P; van Meerbeeck JP; Smits E; Marcq E
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
